• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Home » Conference Paper

Conference Paper

Cyber & formal methods publications January 1, 2016 Conference Paper

Diagnosis cloud: Sharing knowledge across cellular networks

SRI International

This paper presents a novel diagnosis cloud framework that enables the extraction and transfer of knowledge from one network to another. It also presents use cases and requirements. We present the implementation details of the diagnosis cloud framework for two specific types of models: topic models and Markov Logic Networks (MLNs).

Speech & natural language publications September 1, 2015 Conference Paper

Mitigating the effects of non-stationary unseen noises on language recognition performance

Aaron Lawson, Martin Graciarena, Mitchell McLaren

We introduce a new dataset for the study of the effect of highly non-stationary noises on language recognition (LR) performance. 

Biomedical sciences publications August 1, 2014 Conference Paper

Development of an Agonist of the TGF-Beta Signaling Pathway to Treat Alzheimer’s Disease

Carol Green

Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to progressive cognitive dysfunction. Current knowledge of the processes leading to AD is still limited, and no effective treatments are available. Because neurodegeneration is associated with injury and activation of innate immune responses in the brain, drugs that could mimic the beneficial aspects of this response are potential therapeutic candidates. The cytokine transforming growth factor (TGF)-?1 is an organizer of the brain’s response to injury and has been shown to have neuroprotective effects in models of brain injury and degeneration. Recombinant TGF-?1 has been used to treat various forms of brain injury in vivo but delivery is not suitable for human use. Studies from our lab have demonstrated that TGF-?1 can reduce the overall accumulation of A?, a key factor in AD pathogenesis, in mouse models for AD and in cell culture. Numerous studies have also demonstrated that TGF-?1 is a potent neurotrophic factor, although high-level chronic TGF-?1 production can also be detrimental. Recently, we reported that reduced TGF-?1 expression in vivo or in cultured neurons increases neurodegeneration. Additional studies show that reducing TGF-? signaling in neurons of a mouse model for AD increases A? accumulation and neurodegeneration and that TGF-? receptor expression is reduced in human AD brains. We have identified bioactive small molecule chemical compounds that can activate the TGF-? signaling pathway in hippocampal neurons of mice and that pass the blood-brain barrier. With reporter cell lines for the TGF-? signaling pathway we screened a diverse small molecule drug library and identified several compounds that are able to activate the reporter system in vitro and in TGF-? reporter mice in vivo. The compounds induce specific TGF-?-responsive genes in cell culture consistent with Smad dependent activation of the TGF-? pathway. These chemicals share common properties from which we propose here to derive a lead compound within 5 years. This project includes structure activity relationship analysis of identified active compounds, medicinal chemistry, toxicology and pharmacology in a subcontract with SRI International. Compounds will be tested in neuroprotection and neurotoxicity assays in cell culture and in TGF-? reporter mice in vivo. The two most promising compounds will then be tested in an in vivo model of neurodegeneration and in a mouse model for AD. Part of the in vivo analysis on neurodegeneration will be done in collaboration with researchers at UCSD. At the end of our studies we propose to have for the first time a novel neuroprotective and amyloid reducing investigational new drug based on the TGF-? signaling pathway for testing in patients with AD.

Digital learning publications June 1, 2014 Conference Paper

Using Analytics for Improving Implementation Fidelity in a Large Scale Efficacy Trial

SRI International

Information & computer science publications May 1, 2014 Conference Paper

Highly Accurate Phonetic Segmentation Using Boundary Correction Models and System Fusion

SRI International

Accurate phone-level segmentation of speech remains an important task for many subfields of speech research. We investigate techniques for boosting the accuracy of automatic phonetic segmentation based on HMM acoustic-phonetic models. In prior work we were able to improve on state-of-the-art alignment accuracy by employing special phone boundary HMM models, trained on phonetically segmented training data, in conjunction with a simple boundary-time correction model. Here we present further improved results by using more powerful statistical models for boundary correction that are conditioned on phonetic context and duration features. Furthermore, we find that combining multiple acoustic front-ends gives additional gains in accuracy, and that conditioning the combiner on phonetic context and side information helps. Overall, we reduce segmentation errors on the TIMIT corpus by almost one half, from 93.9% to 96.8% boundary accuracy with a 20-ms tolerance.

Biomedical sciences publications February 1, 2014 Conference Paper

Mechanism of Action of Flufirvitide, a Peptide Inhibitor of Influenza Virus Infection

SRI International

Influenza is an infectious disease typically transmitted through the air. It is responsible for seasonal epidemics affecting millions of people, and sporadic global pandemics. Influenza infection is a membrane fusion‐dependant process, occurring in the endosome of the host cell after viral binding and endocytosis. The virus‐host membrane fusion process is mediated by hemagglutinin (HA), a viral surface glycoprotein. Studies show that when the virus is subjected to low pH in the endosome, the HA protein partially unfolds and changes conformation, exposing the fusion initiation region (FIR). A 16 amino acid peptide sequence (Flufirvitide) derived from the fusion initiation region of the HA protein has shown effective inhibition of influenza virus infection.  It is hypothesized that there is an interaction between the peptide and the FIR which inhibits fusion of the virus to the host cell. Plaque inhibition assays and animal studies show high efficacy of the peptide against the virus. We are currently developing biochemical and biophysical assays to study the interaction between Flufirvitide and HA. Circular Dichroism studies show that the peptide has a random coil conformation at pH 7 and higher. To elucidate the mechanism of fusion inhibition, the interaction between peptide and HA is being investigated with immunodetection, immunoprecipitation, and florescence techniques. Additionally, binding and interaction of the peptide with the intact virus is being studied by using Cryo‐electron microscopy.

Biomedical sciences publications November 1, 2013 Conference Paper

Varenicline Markedly Decreases Antipsychotic-Induced Tardive Dyskinesia in a Rodent Model

SRI International

Tardive dyskinesia is a potentially irreversible drug-induced movement disorder that arises as a side effect of antipsychotic therapy. Antipsychotics form the mainstay of treatment for schizophrenia and bipolar disorder and, in addition, are increasingly being prescribed for major depressive disorder, autism, attention deficit hyperactivity disorder, obsessive compulsive disorder and post-traumatic stress disorder. There is therefore a clear need for therapies to reduce tardive dyskinesia. Our recent studies showed that nicotine administration decreased haloperidol-induced vacuous chewing movements (VCMs) in a rat model of tardive dyskinesia. The present experiments demonstrate that nicotine (300 µg/ml in drinking water) also reduced VCMs (50%) in mice whether haloperidol was given via constant infusion (subcutaneous pellet) or daily injection. The nicotine-mediated decline is thus observed across species using various haloperidol treatment regimens. We then tested the effect of varenicline, an agonist that interacts with multiple nicotinic receptor subtypes. Low dose varenicline (0.1 mg/kg) decreased haloperidol-induced VCMs to a much greater extent (~90%) than nicotine (~50%). Since varenicline also acts at serotonergic receptors, we tested the effect of nicotine in combination with a selective serotonergic receptor drug 8-OH-DPAT (0.3 mg/kg). Nicotine or 8-OH-DPAT treatment alone decreased haloperidol-induced VCMs by ~60%, while combined administration reduced VCMs to a significantly greater extent than either drug alone (83%). These data are the first to show that drugs acting at both nicotinic and serotonergic receptors result in a pronounced decline in antipsychotic-induced VCMs. Drugs such as varenicline that act at both receptors may thus represent a novel therapy for reducing tardive dyskinesia.

Cyber & formal methods publications September 1, 2013 Conference Paper

Safety Verification for Linear Systems

SRI International

Cyber & formal methods publications September 1, 2013 Conference Paper

Logic and Epistemology in Safety Cases

John Rushby

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • Go to Next Page »

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}